Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 3/20 | 0.43 |
| ▸ | CDK2 | P24941 | 3/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ASPH | Q12797 | 1/20 | 0.35 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.35 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4258570 | 0.91 | CCNA2 (0.40) | CCNA2CDK2CCNA1AURKAPLK1 | |
| Trifluoroacetic Acid SCHEMBL6798826 | 0.82 | IKBKB (0.37) | AURKAPLK1L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL6792909 | 0.82 | MAPKAPK2 (0.37) | CCNA2CDK2CCNA1AURKAPLK1 | |
| Trifluoroacetic Acid SCHEMBL6792906 | 0.82 | MAPKAPK2 (0.37) | CCNA2CDK2CCNA1AURKAPLK1 | |
| SCHEMBL4264409 | 0.78 | MAPKAPK2 (0.56) | MAPKAPK2 | |
| Trifluoroacetic Acid SCHEMBL6794251 | 0.77 | POLB (0.35) | CCNA2CDK2CCNA1AURKAPLK1 | |
| Trifluoroacetic Acid SCHEMBL6794255 | 0.77 | POLB (0.35) | CCNA2CDK2CCNA1AURKAPLK1 | |
| Trifluoroacetic Acid SCHEMBL6787950 | 0.77 | PARP1 (0.35) | CCNA2CDK2CCNA1AURKAPLK1 | |
| Trifluoroacetic Acid SCHEMBL6794131 | 0.77 | GRM2 (0.33) | HRH1L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL6794973 | 0.77 | HRH1 (0.34) | HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
| US-9023787-B2 | MAPKAP kinase-2 as a specific target for blocking proliferation of P53-defective | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140037755-A1 | Mapkap Kinase-2 as a Specific Target for Blocking Proliferation of P53-Defective Cells | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-02-06 | — | — | US | disclosed |
| US-8440610-B2 | Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120252737-A1 | Methods for Diagnosing and Treating Cancer | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-10-04 | — | — | US | disclosed |
| US-20090181468-A1 | Methods and compositions for treating cellular proliferative diseases | YAFFE MICHAEL B | 2009-07-16 | — | — | US | disclosed |
| US-20090010927-A1 | Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-01-08 | — | — | US | disclosed |
| US-20060115453-A1 | Methods and compositions for treating cellular proliferative diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060115453-A1 | Methods and compositions for treating cellular proliferative diseases | MKI67, TP53, CCNC | CCNA2 11/4885CDK2 29/4885CCNA1 9/4885 |
| US-20140037755-A1 | Mapkap Kinase-2 as a Specific Target for Blocking Proliferation of P53-Defective Cells | MAPKAPK2, MAPKAP1, MAP3K2 | CCNA2 270/4885CDK2 77/4885CCNA1 327/4885 |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | CCNA2 270/4885CDK2 29/4885CCNA1 527/4885 |
| US-20090010927-A1 | Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells | MAPKAPK2, MAPKAP1, MAP3K2 | CCNA2 270/4885CDK2 77/4885CCNA1 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.